From a press release on Senator Patrick Leahy's website:
One thing I don't like about the Leahy letter is the following statement; "...As a result, Myriad may continue to be the only company able to provide women with the genetic testing they need..." That "may" doesn't make clear that there are presently at least two cases pending challenging Myriad's genetic testing program. But these two labs being sued by Myriad are not the only ones offering the tests. According to one source:
" Emory Genetics Lab, GeneDx, Pathway Genomics, Ethigen, and the University of Washington announced they would offer BRCA testing after the Supreme Court's ruling in AMP v. Myriad."
Thursday, July 18, 2013
Friday, July 12, 2013
The following is excerpted from a very lengthy and prolix statement.
Universal Declaration on the Human Genome and Human Rights
The Universal Declaration on the Human Genome and Human Rights was adopted unanimously and by acclamation at UNESCO's 29th General Conference on 11 November 1997. The following year, the United Nations General Assembly endorsed the Declaration.
|Universal Declaration on the Human Genome and Human Rights|
11 November 1997
|The General Conference,|
Proclaims the principles that follow and adopts the present Declaration.
A. Human dignity and the human genome
The human genome underlies the fundamental unity of all members of the human family, as well as the recognition of their inherent dignity and diversity. In a symbolic sense, it is the heritage of humanity.
(a) Everyone has a right to respect for their dignity and for their rights regardless of their genetic characteristics.
(b) That dignity makes it imperative not to reduce individuals to their genetic characteristics and to respect their uniqueness and diversity.
The human genome, which by its nature evolves, is subject to mutations. It contains potentialities that are expressed differently according to each individual’s natural and social environment, including the individual’s state of health, living conditions, nutrition and education.
The human genome in its natural state shall not give rise to financial gains.
Here is the Washington Post's pessimistic view of Myriad chances in overcoming AMP v Myriad's holding of invalidity of gene patents. I am not so pessimistic. I think Myriad's claims can be overcome or designed around.
The NYT reports that Myriad Genetics has sued two competitors for infringing its patents, citing the numerous claims of the patents which were not declared invalid by thee Supreme Court. Here is a link to the article.